Tashkent, Uzbekistan (UzDaily.com) —  AstraZeneca is actively collaborating with Uzbekistan’s medical community to introduce modern strategies for managing type 2 diabetes (T2D) and improving patient outcomes. 

Type 2 diabetes is a significant health concern in Uzbekistan. According to the Republican Specialized Scientific-Practical Center of Endocrinology under the Ministry of Health, over 377,000 people—more than 1% of the population—suffer from this condition. 

Government programs aimed at improving access to effective treatments, including those under the "Uzbekistan-2030" strategy, are already in place. However, beyond access, updating local treatment protocols to align with international standards is a pressing challenge. AstraZeneca is contributing to this effort by supporting numerous educational initiatives for healthcare professionals and patients alike. 

A key milestone was the registration in Uzbekistan in 2021 of an original AstraZeneca drug, proven effective and safe for T2D management in both international studies and extensive clinical practice. 

The company hosts scientific and practical events featuring Uzbek and international experts, fostering knowledge exchange and professional development. 

In addition to working with healthcare professionals, AstraZeneca prioritizes public education to raise awareness about T2D and the importance of timely treatment. The company aims to expand access to innovative glucose-lowering therapies, improving patients’ quality of life and disease outcomes. 

AstraZeneca’s commitment to advancing diabetes care in Uzbekistan underscores its dedication to improving public health and enhancing the lives of patients with this widespread condition. The combination of government initiatives and pharmaceutical industry support, exemplified by AstraZeneca, provides a solid foundation for combating T2D in Uzbekistan.